The Drug Enforcement Administration will “likely” reschedule marijuana, following federal health regulators’ Aug. 29 recommendation, according to a government analysis.
The DEA confirmed to Congress in 2020 that it is “bound” by law to defer to the U.S. Department of Health and Human Services (HHS) on matters of science and health, according to a Sept. 13 report by the Congressional Research Service (CRS), the federal government’s public-policy think tank.
The analysis means the nation’s drug police are unlikely to block a potentially revolutionary advance in federal drug policy.
And that has major implications for the U.S. marijuana industry as well as cannabis users seeking federal jobs or assistance, including military service and public housing.
The “DEA has testified in response to questioning at a congressional hearing in 2020 that it is bound by (Food and Drug Administration) recommendations on scientific and medical matters, and if past is prologue it could be likely that DEA will reschedule marijuana according to HHS’s recommendation,” the researchers wrote.
“(The) CRS is unaware of any instance where DEA has rejected an FDA recommendation to reschedule.”
Legal scholars and drug-policy experts share the view of CRS, according to an MJBizDaily report.
To read more, click on MJBIzDaily